Proactive Investors - Run By Investors For Investors

Pharmaxis enters trading halt ahead of share placement

The company plans to raise funds by way of a share placement.
capital raising concept with documents and reading glasses
Further details regarding the capital raising are expected by Tuesday

Pharmaxis Ltd (ASX:PXS) has been granted a trading halt by the ASX pending the release of information regarding a share placement.

The company’s shares will remain halted until the earlier of, the release of relevant information, or, the commencement of trading next Tuesday.

READ: Pharmaxis powering ahead with phase I LOXL2 studies

Pharmaxis is an established pharmaceutical research company working on new therapies to treat inflammatory and fibrotic diseases.

This includes liver disease NASH, pulmonary fibrosis, kidney and liver fibrosis, inflammatory bowel diseases and cancer.

The company finished the June quarter with just over $31 million in cash.

View full PXS profile View Profile

Pharmaxis Ltd Timeline

Related Articles

skin cream
October 25 2018
The cream is currently undergoing its first-in-human studies, with researchers assessing its skin irritancy, moisturisation potential and skin barrier function
February 21 2019
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier
scientist in lab
February 26 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use